3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Melanoma
10
Glioma
9
Brain Neoplasms
9
Neoplasms
3
Multiple Myeloma
3
Histiocytosis, Langerhans-Cell
3
Glioblastoma
3
Astrocytoma
3
Thyroid Carcinoma, Anaplastic
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neurofibroma, Plexiform
2
Neurocytoma
2
Neuroblastoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Ganglioneuroma
2
Ganglioglioma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Nonseminomatous germ cell tumor
1
Interventions
Radiosurgery
3
pazopanib
2
trametinib
1
motexafin gadolinium
1
dabrafenib
1
alectinib
1
Surveys and Questionnaires
1
Specimen Handling
1
Sodium Chloride
1
Patient-Specific Modeling
1
Oncolytic Virotherapy
1
Observation
1
Memantine
1
Magnetic Resonance Spectroscopy
1
MLN 8237
1
Cytoreduction Surgical Procedures
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
dabrafenib
×
CNS
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled